These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux. Miner PB Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267 [TBL] [Abstract][Full Text] [Related]
44. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD Dis Esophagus; 2017 May; 30(5):1-9. PubMed ID: 28375448 [TBL] [Abstract][Full Text] [Related]
45. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment. Spechler SJ Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563 [TBL] [Abstract][Full Text] [Related]
46. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963 [TBL] [Abstract][Full Text] [Related]
47. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Kang H; Kim BJ; Choi G; Kim JG Medicine (Baltimore); 2018 Sep; 97(39):e12574. PubMed ID: 30278564 [TBL] [Abstract][Full Text] [Related]
48. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy. Soricelli E; Casella G; Baglio G; Maselli R; Ernesti I; Genco A Surg Obes Relat Dis; 2018 Jun; 14(6):751-756. PubMed ID: 29571635 [TBL] [Abstract][Full Text] [Related]
49. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Freedberg DE; Kim LS; Yang YX Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716 [TBL] [Abstract][Full Text] [Related]
50. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring. Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y; J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590 [TBL] [Abstract][Full Text] [Related]
51. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo Schey R; Alla SP; Midani D; Parkman HP Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467 [TBL] [Abstract][Full Text] [Related]
52. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Caro JJ; Salas M; Ward A Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776 [TBL] [Abstract][Full Text] [Related]
53. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281 [TBL] [Abstract][Full Text] [Related]
54. Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder. Soll AH; Fass R Clin Cornerstone; 2003; 5(4):2-14; discussion 14-7. PubMed ID: 15101491 [TBL] [Abstract][Full Text] [Related]
55. Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: an exploratory, post-market, open-label study. Boarino V; Raguzzi I; Marocchi M; Merighi A Turk J Gastroenterol; 2020 Jun; 31(6):466-473. PubMed ID: 32721918 [TBL] [Abstract][Full Text] [Related]
56. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Fass R; Cahn F; Scotti DJ; Gregory DA Surg Endosc; 2017 Dec; 31(12):4865-4882. PubMed ID: 28233093 [TBL] [Abstract][Full Text] [Related]
57. On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis. Kang SJ; Jung HK; Tae CH; Kim SY; Lee KJ J Neurogastroenterol Motil; 2022 Jan; 28(1):5-14. PubMed ID: 34980685 [TBL] [Abstract][Full Text] [Related]
58. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310 [TBL] [Abstract][Full Text] [Related]
59. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease. Watson TJ; Peters JH Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131 [TBL] [Abstract][Full Text] [Related]
60. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y; Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]